...
...
Next Story

Coronavirus pandemic: India approves emergency use of remdesivir to treat COVID-19 patients

Updated on: Jun 3, 2020, 16:04:37 IST
Bengaluru | By
Prefer HTon Google
FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. (Reuters)
FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. (Reuters)
Advertisement

Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical trials and is at the forefront of the battle against COVID-19, which has no approved treatment or vaccine.

India’s government said on Tuesday it has approved Gilead Sciences Inc’s antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients.

Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical trials and is at the forefront of the battle against COVID-19, which has no approved treatment or vaccine.

The drug was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators. The drug is being administered in some countries under compassionate use rules.

“(Remdesivir) approved on June 1 under emergency use with condition for five dose administration,” the Drugs Controller General of India said in an email statement.

The approval comes a day after the U.S. drugmaker reported that remdesivir showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.

The drug has been approved for the treatment of adults and children with severe COVID-19, the Indian Express newspaper reported https://bit.ly/3cpFces on Tuesday, citing sources.

Gilead did not respond to an email seeking further details.

The company signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan, including Cipla Ltd and Jubilant Life Sciences Ltd, to expand supply of the drug.

As of Tuesday, India has 198,706 cases of coronavirus and has recorded 5,598 deaths, health ministry data showed https://www.mohfw.gov.in.

Governments are racing to bolster supplies of remdesivir, with European and South Korean authorities vying for the potential COVID-19 treatment.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed. )

Follow more stories on Facebook and Twitter

 
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
SHARE THIS ARTICLE ON